DNA 및 유전자 클로닝 서비스 시장 규모, 점유율 및 동향 분석 보고서 : 서비스별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

DNA And Gene Cloning Services Market Summary

The global DNA and gene cloning services market size was estimated at USD 2.51 billion in 2024 and is projected to reach USD 9.46 billion by 2033, growing at a CAGR of 15.98% from 2025 to 2033. Advancements in DNA and gene cloning technology, rising acceptance of gene therapy, and increasing demand for personalized medicine are some of the factors driving market growth.

Need to reduce turnaround time, cost, and technical complexity

The need to reduce turnaround times, cut expenses, and avoid the technical difficulties of internal workflows is a major driver of demand for DNA and gene cloning services. For biotech startups, academic labs, and pharmaceutical companies, traditional cloning is costly and time-consuming due to the need for specialized equipment, controlled lab environments, and qualified molecular biologists. Organizations are increasingly outsourcing cloning to obtain advanced capabilities without delays or investment in internal infrastructure due to the growing competition in drug discovery, synthetic biology, and gene therapy.

Genetic research and applications are changing because of recent technological developments in the DNA and gene cloning industries. Automated cloning, synthetic biology, and AI-driven gene design innovations are drastically cutting costs, streamlining complicated workflows, and speeding up turnaround times. These advancements speed up the development of therapeutics, diagnostics, and research applications by increasing efficiency and accuracy, as well as making customized gene synthesis and cloning services more accessible.

Global DNA And Gene Cloning Services Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global DNA and gene cloning services market report based on service, application, end use, and region:

• Services Outlook (Revenue, USD Million, 2021 - 2033)
• Gene Synthesis
• Custom Cloning
• Sub-cloning
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• DNA Sequencing
• Mutagenesis
• Genotyping
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• CMOs & CROs
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Service Segment
  • 1.2.2. Application Segment
  • 1.2.3. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. DNA and Gene Cloning Services Market Variables and Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Need to reduce turnaround time, cost, and technical complexity
    • 3.2.1.2. Demand for customized constructs for CRISPR & gene editing
    • 3.2.1.3. Rising acceptance of gene therapies
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Ethical challenges with the use of gene cloning and synthesis technology
• 3.3. DNA and Gene Cloning Services Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. DNA and Gene Cloning Services Market: Service Estimates & Trend Analysis

• 4.1. Service Segment Dashboard
• 4.2. Global DNA and Gene Cloning Services Market Service Movement Analysis
• 4.3. Global DNA and Gene Cloning Services Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
• 4.4. Gene Synthesis
  • 4.4.1. Gene synthesis market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Custom Cloning
  • 4.5.1. Custom cloning market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Sub-cloning
  • 4.6.1. Sub-cloning market estimates and forecasts 2021 to 2033 (USD Million)
• 4.7. Others
  • 4.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. DNA and Gene Cloning Services Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global DNA and Gene Cloning Services Market Application Movement Analysis
• 5.3. Global DNA and Gene Cloning Services Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. DNA Sequencing
  • 5.4.1. DNA sequencing market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Mutagenesis
  • 5.5.1. Mutagenesis market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Genotyping
  • 5.6.1. Genotyping market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. DNA and Gene Cloning Services Market: End Use Estimates & Trend Analysis

• 6.1. End Use Segment Dashboard
• 6.2. Global DNA and Gene Cloning Services Market End Use Movement Analysis
• 6.3. Global DNA and Gene Cloning Services Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Academic & Research Institutes
  • 6.4.1. Academic & research institutes market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Pharmaceutical & Biotechnology Companies
  • 6.5.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. CMOs & CROs
  • 6.6.1. CMOs & CROs market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. DNA and Gene Cloning Services Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. U.S.
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. Regulatory framework
  • 7.4.2. Canada
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Regulatory framework
  • 7.4.3. Mexico
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. Regulatory framework
• 7.5. Europe
  • 7.5.1. UK
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Regulatory framework
  • 7.5.2. Germany
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Regulatory framework
  • 7.5.3. France
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Regulatory framework
  • 7.5.4. Italy
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Regulatory framework
  • 7.5.5. Spain
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Regulatory framework
  • 7.5.6. Norway
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Regulatory framework
  • 7.5.7. Sweden
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.7.3. Competitive scenario
    • 7.5.7.4. Regulatory framework
  • 7.5.8. Denmark
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.8.3. Competitive scenario
    • 7.5.8.4. Regulatory framework
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Regulatory framework
  • 7.6.2. China
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2.4. Regulatory framework
  • 7.6.3. India
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Regulatory framework
  • 7.6.4. Australia
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Regulatory framework
  • 7.6.5. South Korea
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Regulatory framework
  • 7.6.6. Thailand
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Regulatory framework
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Regulatory framework
  • 7.7.2. Argentina
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Regulatory framework
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Regulatory framework
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Regulatory framework
  • 7.8.3. UAE
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. Regulatory framework
  • 7.8.4. Kuwait
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.4.3. Competitive scenario
    • 7.8.4.4. Regulatory framework

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Bio-Techne
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Service benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Charles River Laboratories
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Service benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Eurofins Scientific
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Service benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. GenScript
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Service benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Danaher Corporation
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Service benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Syngene International Limited
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Service benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Twist Bioscience
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Service benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Thermo Fisher Scientific, Inc.
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Service benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Merck KGaA
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Service benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Curia Global, Inc.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Service benchmarking
    • 8.4.10.4. Strategic initiatives